Nonneuronal dopamine.
Soares-da-Silva
P
P
Institute of Pharmacology and Therapeutics, Porto, Portugal.
Vieira-Coelho
M A
MA
D000316:Adrenergic alpha-Agonists / Q000494:pharmacology; D000584:Amiloride / Q000031:analogs & derivatives / Q000494:pharmacology; D000818:Animals; D001545:Benserazide / Q000494:pharmacology; D001692:Biological Transport; D000068438:Brimonidine Tartrate; D002394:Catechol O-Methyltransferase / Q000378:metabolism; D004298:Dopamine / Q000378:metabolism*; D007668:Kidney / Q000502:physiology*; D007672:Kidney Cortex / Q000502:physiology; D007684:Kidney Tubules / Q000187:drug effects / Q000502:physiology; D007980:Levodopa / Q000378:metabolism; D008954:Models, Biological; D008995:Monoamine Oxidase / Q000378:metabolism; D010656:Phenylephrine / Q000494:pharmacology; D011810:Quinoxalines / Q000494:pharmacology; D017923:Sodium-Hydrogen Exchangers / Q000187:drug effects / Q000378:metabolism
D000316:Adrenergic alpha-Agonists; D011810:Quinoxalines; D017923:Sodium-Hydrogen Exchangers; D010656:Phenylephrine; D007980:Levodopa; D000068438:Brimonidine Tartrate; D001545:Benserazide; D000584:Amiloride; D008995:Monoamine Oxidase; D002394:Catechol O-Methyltransferase; D004298:Dopamine; C039614:ethylisopropylamiloride